Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMatthias Tschoep, MD
About
Research
Publications
2026
FGF21 reduces ER stress by enhancing the unfolded protein and integrated stress responses through increased sulfide signaling
Grandl G, König A, Metzger F, Liskiewicz A, Hefele T, Nason S, Novikoff A, Al-Refaie N, Rahman M, Khalil A, Zhang Q, Collden G, Finan B, Douros J, Habegger K, Cebrian-Serrano A, Hauck S, Tschöp M, Müller T. FGF21 reduces ER stress by enhancing the unfolded protein and integrated stress responses through increased sulfide signaling. Cell Metabolism 2026 PMID: 42302784, DOI: 10.1016/j.cmet.2026.05.011.Peer-Reviewed Original ResearchUnfolded protein responseER stressSulfide signalingEndoplasmic reticulumProtein folding stressPhysiological roleIntegrated stress responsePharmacological inhibitionIntracellular actionProximity labelingS productionCellular homeostasisProtein responsePhysiological levelsUnfolded proteinsCellular repair mechanismsActions of FGF21Fibroblast growth factor 21Stress responsePhysiological functionsProteinRepair mechanismsFGF21 actionFGF21Metabolic actionsAuthor Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments
Becker M, Kälin S, Neubig A, Lauber M, Opaleva D, Hipp H, Salb V, Ott V, Legutko B, Kälin R, Hippich M, Scherm M, Nascimento L, Serr I, Hosp F, Nikolaev A, Mohebiany A, Krueger M, Flachmeyer B, Pfaffl M, Haase B, Yi C, Dietzen S, Bopp T, Woods S, Waisman A, Weigmann B, Mann M, Tschöp M, Daniel C. Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments. Nature Communications 2026, 17: 4414. PMID: 42151187, PMCID: PMC13184267, DOI: 10.1038/s41467-026-73173-2.Peer-Reviewed Original ResearchPublisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
Liskiewicz D, Novikoff A, Khalil A, Akindehin S, Campbell J, Candela P, Castelino R, Coupland C, Culot M, Dodson W, Douros J, Embring H, Feuchtinger A, Finan B, Garcia-Caceres C, Gao X, Gosselet F, Grandl G, Gutgesell R, Haas D, Jastroch M, Karaoglu E, Kakimoto P, Kaltenbach A, Keuper M, Kusminski C, Leander D, Liskiewicz A, Liu X, Maity-Kumar G, Martinez S, Mowery S, Nogueiras R, Paisley M, Perez-Tilve D, Petersen P, Pfluger P, Prakash S, Steffens S, Cebrian-Serrano A, Tost M, Wean J, Weber C, Yoshida J, Gerhart-Hines Z, Horvath T, Scherer P, Seeley R, DiMarchi R, Tschöp M, Krahmer N, Knerr P, Müller T. Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature 2026, 654: e11-e11. PMID: 42151694, PMCID: PMC13233300, DOI: 10.1038/s41586-026-10619-z.Peer-Reviewed Original ResearchGLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
Liskiewicz D, Novikoff A, Khalil A, Akindehin S, Campbell J, Candela P, Castelino R, Coupland C, Culot M, Dodson W, Douros J, Embring H, Feuchtinger A, Finan B, Garcia-Caceres C, Gao X, Gosselet F, Grandl G, Gutgesell R, Haas D, Jastroch M, Karaoglu E, Kakimoto P, Kaltenbach A, Keuper M, Kusminski C, Leander D, Liskiewicz A, Liu X, Maity-Kumar G, Martinez S, Mowery S, Nogueiras R, Paisley M, Perez-Tilve D, Petersen P, Pfluger P, Prakash S, Steffens S, Cebrian-Serrano A, Tost M, Wean J, Weber C, Yoshida J, Gerhart-Hines Z, Horvath T, Scherer P, Seeley R, DiMarchi R, Tschöp M, Krahmer N, Knerr P, Müller T. GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature 2026, 653: 776-785. PMID: 42056522, PMCID: PMC13190304, DOI: 10.1038/s41586-026-10427-5.Peer-Reviewed Original ResearchCo-agonismAnti-inflammatory effectsMetabolic efficacyPharmacological inhibitionGLP-1RIncretin receptor signalingReceptor knockout miceMetabolic actionsPhase 3 trialClinical phase 3 trialManagement of obesityTreatment of obesityBlood glucose-lowering effectGlucose-lowering effectStimulation of insulin secretionBody weight-reducingInsulin-resistant miceFood intakeMetabolic dysfunctionReceptor signalingEffective drugsInsulin sensitivityPPAR actionMiceTargeted deliveryGIPR:GCGR co-agonism restores normal weight in obese rodents
Perez-Tilve D, Zhang F, Zhang Y, Lohman K, Sorrell J, Vick A, Müller T, Tschöp M, DiMarchi R. GIPR:GCGR co-agonism restores normal weight in obese rodents. Molecular Metabolism 2026, 108: 102365. PMID: 41997446, PMCID: PMC13141540, DOI: 10.1016/j.molmet.2026.102365.Peer-Reviewed Original ResearchGLP-1R KO miceGLP-1RGLP-1KO miceCo-agonistKnock-out (KO) miceBody weightFunctional GLP-1RCorrection of obesityAdverse GI effectsExcess body weightPair-feeding studyGLP-1R agonismTri-agonistsCo-agonismNormal weightGLP-1 activityGLP-1 agonismCAMP productionDIO miceObese rodentsFood intakeGIPR agonismObese miceIndirect calorimetryGlucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
Nauck M, Tuttle K, Tschöp M, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet 2026, 407: 892-908. PMID: 41547366, DOI: 10.1016/s0140-6736(25)02105-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGLP-1 receptor agonistsGlucose-dependent insulinotropic polypeptideReceptor agonistsGLP-1Type 2 diabetesHeart failureDual glucose-dependent insulinotropic polypeptideEstimated glomerular filtration rateDose-escalation regimensObstructive sleep apnoeaAdverse gastrointestinal eventsGlomerular filtration ratePrevention of fibrosisPrevention of type 2 diabetesAdverse cardiovascular eventsObesity-related conditionsClinical development programmeTreatment of obesityRegression of steatosisEvidence of efficacySleep apnoeaGastrointestinal eventsSymptomatic improvementOral treatmentCardiovascular events
2025
Publisher Correction: GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
Gutgesell R, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros J, Knerr P, Finan B, DiMarchi R, Sloop K, Samms R, Theis F, Tschöp M, Müller T. Publisher Correction: GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nature Metabolism 2025, 7: 1299-1299. PMID: 40360757, PMCID: PMC12198006, DOI: 10.1038/s42255-025-01308-8.Commentaries, Editorials and LettersGIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
Gutgesell R, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros J, Knerr P, Finan B, DiMarchi R, Sloop K, Samms R, Theis F, Tschöp M, Müller T. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nature Metabolism 2025, 7: 1282-1298. PMID: 40301583, PMCID: PMC12198009, DOI: 10.1038/s42255-025-01294-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptide receptorFood intake effectsGLP-1R signalingGLP-1RBody weightFood intakeNervous systemDorsal vagal complexBody weight lossGLP-1R agonismCentral nervous systemPeripheral nervous systemGABAergic neuronsVagal complexMale miceSingle-nucleus RNA sequencingSynaptic plasticityPolypeptide receptorWeight lossMiceAgonismNeuronsAntagonismGIPRRegulated genesEstrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism
Coupland C, Sun N, Khalil A, Karaoglu Ö, Liskiewicz A, Liskiewicz D, Grandl G, Akindehin S, Maity G, Yang B, Finan B, Knerr P, Douros J, Walch A, DiMarchi R, Tschöp M, Müller T, Novikoff A. Estrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism. Molecular Metabolism 2025, 96: 102136. PMID: 40204014, PMCID: PMC12032945, DOI: 10.1016/j.molmet.2025.102136.Peer-Reviewed Original ResearchConceptsGLP-1R signalingMass spectrometry techniquesGLP-1GLP-1REstrogenic efficacyEstrone-3-sulfateSmall-molecule targetsMolecule conjugatesSatiety-inducing effectsSmall moleculesGlucagon-like peptide 1Conjugation strategyMolecule targetsEstrogenic activityPH-dependent proteolytic activityCo-administrationEstrogen signalingMetabolic outcomesEstrone metabolismSelective deliveryIntracellular mechanismsActive estradiolCargo releaseA once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
Finan B, Douros J, Goldwater R, Hansen A, Hjerpsted J, Hjøllund K, Kankam M, Knerr P, Konkar A, Mowery S, Müller T, Nielsen J, Nygård S, Perez-Tilve D, Raun K, Yang B, Tschöp M, DiMarchi R. A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans. Molecular Metabolism 2025, 96: 102129. PMID: 40139439, PMCID: PMC12051155, DOI: 10.1016/j.molmet.2025.102129.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic peptide receptorTri-agonistsClinical developmentGlycemic controlSubstantial body weight lossSignificant body weight reductionBody weight reductionBody weight lossLowered body weightDose-dependent mannerTreatment cohortsNon-human primatesObesity treatmentObese micePeptide receptorGLP-1RHuman participantsHeart rateWeight lossBody weightGlucagon receptorObesityWeight reductionReceptorsMode of action